Canada High Court Upholds Plavix 'Selection' Patent

Law360, New York (November 6, 2008, 12:00 AM EST) -- In a landmark ruling that could have major implications for generic-drug makers in Canada, the Supreme Court of Canada has held that a selection patent for a key ingredient in the “clot-busting” drug Plavix is valid, dismissing an appeal from Apotex Inc. to invalidate the patent.

The Canadian Supreme Court handed down its unanimous opinion on Thursday in favor of Sanofi-Synthelabo Canada Inc., dismissing Apotex's appeal and also bringing the bar for obviousness in pharmaceutical patent cases in Canada closer to the standard in the U.S....
To view the full article, register now.